367 top medical experts on Acute Erythroblastic Leukemia across 43 countries and 26 U.S. states, including 196 MDs (Physicians). This is based on an objective analysis of their Scientific Publications, Clinical Trials, Medicare, and NIH Grants.

  1. Acute Erythroblastic Leukemia: A myeloproliferative disorder characterized by neoplastic proliferation of erythroblastic and myeloblastic elements with atypical erythroblasts and myeloblasts in the peripheral blood.
  2. Clinical guidelines are the recommended starting point to understand initial steps and current protocols in any disease or procedure:
  3. Broader Categories (#Experts): Acute Myeloid Leukemia (4,896), Myeloproliferative Disorders (3,110).
  4. Clinical Trials ClinicalTrials.gov : at least 83 including 6 Active, 52 Completed, 1 Recruiting
  5. Synonyms: Di Guglielmo's Disease,  Erythremic Myelosis,  Erythroleukemia,  M6 Acute Myeloid Leukemia,  M6 Acute Myeloid Leukemia


  

        

                    


    These expert listings are for individual use without a fee. Biotechs, Pharmaceuticals, Recruiters, Consultants, Investors, Law firms, and other organizations may use this only for quick evaluations (no downloads, screen scraping or using the data) to identify the top medical experts for recruiting, advisory panels, boards, and consulting. Please contact us for licensing, customized queries, feedback and questions.

  1. Hasserjian, Robert P   Hematology   Google Publications
    Department of Pathology, Massachusetts General Hospital, Boston, MA, USA. Top Hospital
    Physician  Highly Published  Case Reports 
    Medical school: Harvard Medical School (MD, 1990)
    Medicare Accepted
    Subjects: Leukemia, Erythroblastic, Acute; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms
    Categories: Pathology; Diagnosis; Classification; Drug Therapy; Etiology; Adverse Effects
    Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification. (2010)
    Pure erythroid leukemia: a reassessment of the entity using the 2008 World Health Organization classification. (2011)

  2. Wang, Sa A   Hematology   Google Publications
    Department of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
    Physician  Highly Published  Case Reports 
    Medical school: Other (MD, 1989)
    Medicare Accepted; Medicare MIPS (Merit-based Incentive Payment System) rating: 68/100
    Subjects: Leukemia, Erythroblastic, Acute; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute; Antineoplastic Agents; Bone Marrow Neoplasms; Classification
    Categories: Diagnosis; Pathology; Classification; Etiology; Ultrastructure; Blood
    Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification. (2010)
    Pure erythroid leukemia: a reassessment of the entity using the 2008 World Health Organization classification. (2011)

  3. Khoury, Joseph D   Anatomic Pathology & Clinical Pathology   Google Publications
    Department of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA. Electronic address: .
    Physician  Highly Published 
    Medical school: Other (MD, 1997)
    Medicare Accepted; Medicare MIPS (Merit-based Incentive Payment System) rating: 68/100
    Subjects: Leukemia, Erythroblastic, Acute; Bone Marrow; Myelodysplastic Syndromes
    Categories: Diagnosis; Classification; Pathology
    Pure erythroid leukemia. (2017)
    Erythroleukemia-historical perspectives and recent advances in diagnosis and management. (2018)

  4. Zuo, Zhuang   Molecular Genetic Pathology   Google Publications
    Department of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
    Physician  Highly Published 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 68/100
    Subjects: Leukemia, Erythroblastic, Acute; Erythroid Cells; Myelodysplastic Syndromes; Classification; Leukemia, Myeloid, Acute; World Health Organization
    Categories: Pathology; Classification; Diagnosis; Methods
    Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification. (2010)
    Acute erythroid leukemia. (2010)

  5. Arber, Daniel A   Anatomic Pathology & Clinical Pathology  Google Publications
    Department of Pathology, University of Chicago, Chicago, IL, USA. Top Hospital
    Physician  Highly Published 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 72.6/100
    Disclosed payments in 2021 from 8 biomedical companies, totalling $17,713, including $8,250 from  Astellas Pharma Global Development
    Subjects: Leukemia, Erythroblastic, Acute; Erythroid Cells; Leukemia, Myeloid, Acute
    Categories: Diagnosis; Drug Therapy; Pathology
    Revisiting erythroleukemia. (2017)
    A reevaluation of erythroid predominance in Acute Myeloid Leukemia using the updated WHO 2016 Criteria. (2018)

  6. Ebert, Benjamin L   Hematology  Google Publications
    Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA. Top Hospital
    Physician 
    Subjects: Leukemia, Erythroblastic, Acute; Gene Editing
    Categories: Genetics
    Genomic subtyping and therapeutic targeting of acute erythroleukemia. (2019)
    Modeling and targeting of erythroleukemia by hematopoietic genome editing. (2021)

  7. Gocke, Christopher D   Molecular Genetic Pathology  Google Publications
    Department of Pathology, The Johns Hopkins University School of Medicine, 600 N. Wolfe St., Pathology Building, Room 401, Baltimore, MD, 21287, USA. Top Hospital
    Physician  Case Reports 
    Medical school: Rutgers R W Johnson Medical School (Cam/New Bruns/Pisc) (MD, 1985)
    Medicare Accepted
    Subjects: Leukemia, Erythroblastic, Acute; Genetic Predisposition to Disease; Germ-Line Mutation; Janus Kinase 2; Myelodysplastic Syndromes; Receptor, ErbB-3
    Categories: Genetics
    A germline ERBB3 variant is a candidate for predisposition to erythroid MDS/erythroleukemia. (2016)
    Molecular evidence of JAK2 p.V617F mutated pure erythroid leukemia arising from polycythemia vera. (2018)

  8. Weinberg, Olga K   Anatomic Pathology   Google Publications
    Department of Pathology, University of Texas Southwestern Medical Center, BioCenter, 2230 Inwood Rd, EB03.220G, Dallas, TX, 75235, USA. . Top Hospital
    Physician 
    Disclosed payments in 2021 from 3 biomedical companies, totalling $7,950, including $7,950 from  JAZZ PHARMACEUTICALS INC.
    Subjects: Leukemia, Erythroblastic, Acute; GATA1 Transcription Factor; Leukemia, Megakaryoblastic, Acute
    Categories: Metabolism; Drug Therapy
    GATA1 Is a Sensitive and Specific Nuclear Marker for Erythroid and Megakaryocytic Lineages. (2017)
    Erythroleukemia: an Update. (2021)

  9. Reichard, Kaaren K   Hematology  Google Publications
    Divisions of Hematopathology and Genomics, Mayo Clinic, Rochester, MN. Top Hospital
    Physician  Case Reports 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 79.7/100
    Disclosed payments in 2021 from 3 biomedical companies, totalling $2,010.5, including $2,010.5 from  Blueprint Medicines Corporation
    Subjects: Leukemia, Erythroblastic, Acute; Myelodysplastic Syndromes; NFI Transcription Factors; RUNX1 Translocation Partner 1 Protein
    Categories: Genetics; Classification
    The clinical outcomes of reclassified erythroleukemia (erythroid/myeloid) as myelodysplastic syndrome (MDS) per 2017 WHO guideline compared to MDS. (2018)
    Novel t(1;8)(p31.3;q21.3) NFIA-RUNX1T1 Translocation in an Infant Erythroblastic Sarcoma. (2021)

  10. Viswanatha, David S   Hematology  Google Publications
    Divisions of Hematopathology and Genomics, Mayo Clinic, Rochester, MN. Top Hospital
    Physician  Case Reports 
    Medical school: Other (MD, 1988)
    Medicare Accepted; Medicare MIPS (Merit-based Incentive Payment System) rating: 79.7/100
    Subjects: Leukemia, Erythroblastic, Acute; Myelodysplastic Syndromes; NFI Transcription Factors; RUNX1 Translocation Partner 1 Protein
    Categories: Genetics; Classification
    The clinical outcomes of reclassified erythroleukemia (erythroid/myeloid) as myelodysplastic syndrome (MDS) per 2017 WHO guideline compared to MDS. (2018)
    Novel t(1;8)(p31.3;q21.3) NFIA-RUNX1T1 Translocation in an Infant Erythroblastic Sarcoma. (2021)

  11. Tang, Guilin   Anatomic Pathology & Clinical Pathology  Google Publications
    a Department of Hematopathology , The University of Texas MD Anderson Cancer Center , Houston , TX , USA ;
    Physician 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 68/100
    Disclosed payments from biomedical company (Astellas Pharma US Inc) in 2021 for $2,736
    Subjects: Leukemia, Erythroblastic, Acute; Myelodysplastic Syndromes; Antineoplastic Agents; Classification; DNA Methylation; Neoplasms, Second Primary
    Categories: Etiology; Classification; Drug Effects; Drug Therapy; Genetics; Methods
    Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification. (2010)
    Myelodysplastic syndromes following therapy with hypomethylating agents (HMAs): development of acute erythroleukemia may not influence assessment of treatment response. (2016)

  12. Patel, Keyur P   Anatomic Pathology & Clinical Pathology  Google Publications
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    Physician 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 68/100
    Disclosed payments in 2021 from 4 biomedical companies, totalling $3,758.37, including $3,000 from  Novartis Pharmaceuticals Corporation
    Subjects: Leukemia, Erythroblastic, Acute; Myelodysplastic Syndromes; Antineoplastic Agents; DNA Methylation; Neoplasms, Second Primary
    Categories: Etiology; Pathology; Classification; Drug Effects; Drug Therapy; Genetics
    Acute erythroid leukemia with <20% bone marrow blasts is clinically and biologically similar to myelodysplastic syndrome with excess blasts. (2016)
    Myelodysplastic syndromes following therapy with hypomethylating agents (HMAs): development of acute erythroleukemia may not influence assessment of treatment response. (2016)

  13. Greipp, Patricia T   Clinical Pathology/Laboratory Medicine  Google Publications
    Divisions of Laboratory Genetics and Genomics, Mayo Clinic, Rochester, MN. Top Hospital
    Physician  Case Reports 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 79.7/100
    Subjects: Leukemia, Erythroblastic, Acute; Myelodysplastic Syndromes; NFI Transcription Factors; RUNX1 Translocation Partner 1 Protein
    Categories: Genetics; Classification
    The clinical outcomes of reclassified erythroleukemia (erythroid/myeloid) as myelodysplastic syndrome (MDS) per 2017 WHO guideline compared to MDS. (2018)
    Novel t(1;8)(p31.3;q21.3) NFIA-RUNX1T1 Translocation in an Infant Erythroblastic Sarcoma. (2021)

  14. Birnbaum, Daniel   Neurology  Google Publications
    U1068 and.
    Physician  Highly Published 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 81.5/100
    Subjects: Leukemia, Erythroblastic, Acute; Biomarkers, Tumor; Chromosome Aberrations; High-Throughput Nucleotide Sequencing; Mutation; Neoplasm Proteins
    Categories: Genetics; Physiology; Methods
    Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers. (2020)
    Molecular characterization of acute erythroid leukemia (M6-AML) using targeted next-generation sequencing. (2016)

  15. Morris, Sarah M   Emergency Medicine  Google Publications
    Department of Pathology, St Jude Childrens Research Hospital, Memphis, TN.
    Physician 
    Subjects: Leukemia, Erythroblastic, Acute; Gene Editing
    Categories: Genetics
    Genomic subtyping and therapeutic targeting of acute erythroleukemia. (2019)
    Modeling and targeting of erythroleukemia by hematopoietic genome editing. (2021)

  16. Meshinchi, Soheil   Pediatric Hematology-Oncology  ClinicalTrials.gov Google Publications
    Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Top Hospital
    Physician 
    Disclosed payments in 2021 from 3 biomedical companies, totalling $2,583.05, including $2,583.05 from  Stemline Therapeutics Inc.
    Subjects: Leukemia, Erythroblastic, Acute
    Categories: Genetics
    Genomic subtyping and therapeutic targeting of acute erythroleukemia. (2019)

  17. Zhang, Jian   Anesthesiology  Google Publications
    Department of Biological Sciences, Columbia University, New York, NY 10027, USA.
    Physician 
    Medical school: Other (MD, 1986)
    Medicare Accepted
    Subjects: Leukemia, Erythroblastic, Acute; Mutation; Myelodysplastic Syndromes; Phosphoproteins; RNA Splicing; RNA Splicing Factors
    Categories: Metabolism
    Disease-Causing Mutations in SF3B1 Alter Splicing by Disrupting Interaction with SUGP1. (2019)

  18. Mullighan, Charles G   Google Publications
    Department of Pathology, St Jude Childrens Research Hospital, Memphis, TN.
    Scientist  Highly Published 
    Relevant US NIH Grant Funding: $10,125,250 over the last 5 years
    Subjects: Leukemia, Erythroblastic, Acute; Gene Editing; Neoplasm Proteins; Transcription Factors; Transcriptome
    Categories: Genetics; Physiology
    Genomic subtyping and therapeutic targeting of acute erythroleukemia. (2019)
    Modeling and targeting of erythroleukemia by hematopoietic genome editing. (2021)

  19. Iacobucci, Ilaria  Google Publications
    Department of Pathology, St Jude Childrens Research Hospital, Memphis, TN.
    Scientist  Highly Published 
    Subjects: Leukemia, Erythroblastic, Acute; Gene Editing; Neoplasm Proteins; Transcription Factors; Transcriptome
    Categories: Genetics; Physiology
    Genomic subtyping and therapeutic targeting of acute erythroleukemia. (2019)
    Modeling and targeting of erythroleukemia by hematopoietic genome editing. (2021)

  20. Orazi, Attilio   Anatomic Pathology & Clinical Pathology  Google Publications
    Department of Pathology and Laboratory Medicine, Weill Cornell Medical College/New York Presbyterian Hospital, New York, NY, USA.
    Physician  Case Reports 
    Disclosed payments in 2021 from 2 biomedical companies, totalling $3,640, including $3,600 from  Novartis Pharmaceuticals Corporation
    Subjects: Leukemia, Erythroblastic, Acute; Erythroid Cells; Leukemia, Myeloid, Acute; Neuroectodermal Tumors, Primitive; Sarcoma, Ewing
    Categories: Diagnosis; Pathology
    Pure Erythroid Leukemia Mimicking Ewing Sarcoma/Primitive Neuroectodermal Tumor in an Infant. (2016)
    A reevaluation of erythroid predominance in Acute Myeloid Leukemia using the updated WHO 2016 Criteria. (2018)

Note:
  1. These experts have limited publications on this topic in our database, so expertise assessment may not be accurate.
  2. Only the top 20 experts are shown. You may filter your results or use the geolocation tabs. Contact us to purchase the entire list.
These expert listings are for individual use without a fee. Biotechs, Pharmaceuticals, Recruiters, Consultants, Investors, Law firms, and other organizations may use this only for quick evaluations (no downloads or screen scraping) to identify the top medical experts for recruiting, advisory panels, boards, and consulting. Please contact us for licensing, customized queries, feedback and questions.

);